Structural studies on mechanisms to activate mutant p53.

Abstract excerpt

The design of a broad-spectrum cancer drug would provide enormous clinical benefits to treat cancer patients. Most of cancerous cells have a mutation in the p53 gene that results in an inactive mutant p53 protein. For this reason, p53 is a prime target for the development of a broad-spectrum cancer drug. To provide the atomic information to rationally design a drug to recover p53 activity is the main goal of the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Crystallography
• Share to Genes, p53
• Share to Mutation